239 related articles for article (PubMed ID: 32805769)
1. TERT promoter mutations in primary and secondary WHO grade III meningioma.
Maier AD; Stenman A; Svahn F; Mirian C; Bartek J; Juhler M; Zedenius J; Broholm H; Mathiesen T
Brain Pathol; 2021 Jan; 31(1):61-69. PubMed ID: 32805769
[TBL] [Abstract][Full Text] [Related]
2. Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis.
Mirian C; Duun-Henriksen AK; Juratli T; Sahm F; Spiegl-Kreinecker S; Peyre M; Biczok A; Tonn JC; Goutagny S; Bertero L; Maier AD; Møller Pedersen M; Law I; Broholm H; Cahill DP; Brastianos P; Poulsgaard L; Fugleholm K; Ziebell M; Munch T; Mathiesen T
J Neurol Neurosurg Psychiatry; 2020 Apr; 91(4):378-387. PubMed ID: 32041819
[TBL] [Abstract][Full Text] [Related]
3. Implementation of TERT promoter mutations improve prognostication of the WHO classification in meningioma.
Mirian C; Grell K; Juratli TA; Sahm F; Spiegl-Kreinecker S; Peyre M; Biczok A; Tonn JC; Goutagny S; Bertero L; Maier AD; Jensen LR; Schackert G; Broholm H; Scheie D; Cahill DP; Brastianos PK; Skjøth-Rasmussen J; Fugleholm K; Ziebell M; Munch TN; Kristensen BW; Mathiesen T
Neuropathol Appl Neurobiol; 2022 Apr; 48(3):e12773. PubMed ID: 34799864
[TBL] [Abstract][Full Text] [Related]
4. Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas.
Yang P; Cai J; Yan W; Zhang W; Wang Y; Chen B; Li G; Li S; Wu C; Yao K; Li W; Peng X; You Y; Chen L; Jiang C; Qiu X; Jiang T;
Neuro Oncol; 2016 Aug; 18(8):1099-108. PubMed ID: 26957363
[TBL] [Abstract][Full Text] [Related]
5. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
Williams EA; Santagata S; Wakimoto H; Shankar GM; Barker FG; Sharaf R; Reddy A; Spear P; Alexander BM; Ross JS; Brastianos PK; Cahill DP; Ramkissoon SH; Juratli TA
Acta Neuropathol Commun; 2020 Oct; 8(1):171. PubMed ID: 33087175
[TBL] [Abstract][Full Text] [Related]
6. TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas.
Biczok A; Kraus T; Suchorska B; Terpolilli NA; Thorsteinsdottir J; Giese A; Tonn JC; Schichor C
J Neurooncol; 2018 Sep; 139(3):671-678. PubMed ID: 29808339
[TBL] [Abstract][Full Text] [Related]
7. TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations.
Labussière M; Di Stefano AL; Gleize V; Boisselier B; Giry M; Mangesius S; Bruno A; Paterra R; Marie Y; Rahimian A; Finocchiaro G; Houlston RS; Hoang-Xuan K; Idbaih A; Delattre JY; Mokhtari K; Sanson M
Br J Cancer; 2014 Nov; 111(10):2024-32. PubMed ID: 25314060
[TBL] [Abstract][Full Text] [Related]
8. De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors.
Peyre M; Gauchotte G; Giry M; Froehlich S; Pallud J; Graillon T; Bielle F; Cazals-Hatem D; Varlet P; Figarella-Branger D; Loiseau H; Kalamarides M
Neuro Oncol; 2018 Jul; 20(8):1113-1121. PubMed ID: 29216385
[TBL] [Abstract][Full Text] [Related]
9. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
10. TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma.
Spiegl-Kreinecker S; Lötsch D; Neumayer K; Kastler L; Gojo J; Pirker C; Pichler J; Weis S; Kumar R; Webersinke G; Gruber A; Berger W
Neuro Oncol; 2018 Nov; 20(12):1584-1593. PubMed ID: 30010853
[TBL] [Abstract][Full Text] [Related]
11. High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression.
Goutagny S; Nault JC; Mallet M; Henin D; Rossi JZ; Kalamarides M
Brain Pathol; 2014 Mar; 24(2):184-9. PubMed ID: 24261697
[TBL] [Abstract][Full Text] [Related]
12. TERT Promoter Mutations and Risk of Recurrence in Meningioma.
Sahm F; Schrimpf D; Olar A; Koelsche C; Reuss D; Bissel J; Kratz A; Capper D; Schefzyk S; Hielscher T; Wang Q; Sulman EP; Adeberg S; Koch A; Okuducu AF; Brehmer S; Schittenhelm J; Becker A; Brokinkel B; Schmidt M; Ull T; Gousias K; Kessler AF; Lamszus K; Debus J; Mawrin C; Kim YJ; Simon M; Ketter R; Paulus W; Aldape KD; Herold-Mende C; von Deimling A
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26668184
[TBL] [Abstract][Full Text] [Related]
13. The prognostic significance of TERT promoter mutations in meningioma: a systematic review and meta-analysis.
Lu VM; Goyal A; Lee A; Jentoft M; Quinones-Hinojosa A; Chaichana KL
J Neurooncol; 2019 Mar; 142(1):1-10. PubMed ID: 30506498
[TBL] [Abstract][Full Text] [Related]
14. ARID1A and TERT promoter mutations in dedifferentiated meningioma.
Abedalthagafi MS; Bi WL; Merrill PH; Gibson WJ; Rose MF; Du Z; Francis JM; Du R; Dunn IF; Ligon AH; Beroukhim R; Santagata S
Cancer Genet; 2015 Jun; 208(6):345-50. PubMed ID: 25963524
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral heterogeneity and
Juratli TA; Thiede C; Koerner MVA; Tummala SS; Daubner D; Shankar GM; Williams EA; Martinez-Lage M; Soucek S; Robel K; Penson T; Krause M; Appold S; Meinhardt M; Pinzer T; Miller JJ; Krex D; Ely HA; Silverman IM; Christiansen J; Schackert G; Wakimoto H; Kirsch M; Brastianos PK; Cahill DP
Oncotarget; 2017 Dec; 8(65):109228-109237. PubMed ID: 29312603
[TBL] [Abstract][Full Text] [Related]
16. TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline.
Sun ZL; Chan AK; Chen LC; Tang C; Zhang ZY; Ding XJ; Wang Y; Sun CR; Ng HK; Yao Y; Zhou LF
Int J Clin Exp Pathol; 2015; 8(9):11485-94. PubMed ID: 26617880
[TBL] [Abstract][Full Text] [Related]
17. Clinical and diffusion parameters may noninvasively predict TERT promoter mutation status in grade II meningiomas.
Shin I; Park YW; Ahn SS; Kang SG; Chang JH; Kim SH; Lee SK
J Neuroradiol; 2022 Jan; 49(1):59-65. PubMed ID: 33716047
[TBL] [Abstract][Full Text] [Related]
18. Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer.
Leão R; Lee D; Figueiredo A; Hermanns T; Wild P; Komosa M; Lau I; Mistry M; Nunes NM; Price AJ; Zhang C; Lipman T; Poyet C; Valtcheva N; Oehl K; Coelho H; Sayyid R; Gomes AM; Prado E Castro L; Sweet J; Vinagre J; Apolónio J; Stephens D; Faleiro I; Fadaak K; Richard PO; Kulkarni G; Zlotta AR; Hamilton RJ; Castelo-Branco P; Tabori U
Int J Cancer; 2019 Apr; 144(7):1676-1684. PubMed ID: 30350309
[TBL] [Abstract][Full Text] [Related]
19. Molecular biological determinations of meningioma progression and recurrence.
Linsler S; Kraemer D; Driess C; Oertel J; Kammers K; Rahnenführer J; Ketter R; Urbschat S
PLoS One; 2014; 9(4):e94987. PubMed ID: 24722350
[TBL] [Abstract][Full Text] [Related]
20. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
